01920nas a2200217   4500000000100000008004100001260003700042653002400079653005700103100000900160700001600169700001400185700001400199700001500213245012300228856009900351300000900450490000700459520122200466022001401688       2023                            d  bPublic Library of Science (PLoS)10aInfectious Diseases10aPublic Health, Environmental and Occupational Health1 aMa Z1 aAugustijn K1 aDe Esch I1 aBossink B1 aDiemert DJ00aPublic-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases  uhttps://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0011760&type=printable  a1-140 v173 a<p>Public-private partnerships (PPPs) for neglected tropical diseases (NTDs) are often studied as an organizational form that facilitates the management and control of the huge costs of drug research and development. Especially the later stages of drug development, including clinical trials, become very expensive. This present study investigates whether and how the type of PPPs influences the initiation and duration of NTD clinical trials. Using the ClinicalTrials.gov database, a dataset of 1175 NTD clinical studies that started between 2000 and 2021 is analyzed based on affiliation information and project duration. For the NTD clinical trials that resulted from PPPs, the collaborating types were determined and analyzed, including the public sector-, private sector-, governmental sector-, and nongovernmental organization-led collaborations. The determinants for the discontinuation of all stopped clinical trials were categorized into scientific-, funding-, political-, and logistic dimensions. The results reveal that public sector-led PPPs were the most common collaborative types, and logistic and scientific issues were the most frequent determinants of stopped clinical trials.</p>

<p>&nbsp;</p>
  a1935-2735